Genes. Glands. Vessels. 💊

Hypertension therapy is entering a new era. The latest Lancet review highlights RNA-based silencing of angiotensinogen, selective aldosterone synthase inhibition, non-steroidal mineralocorticoid receptor antagonists, endothelin receptor blockade, and natriuretic peptide enhancement.

These therapies move beyond ACE inhibitors and ARBs toward durable, mechanism-driven blood pressure control—especially for resistant hypertension and multimorbidity.

The future may not be just lowering pressure, but reshaping pathways. 🔬🫀